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‘An R&D framework would address the question of who pays for essential
medical R&D, dissociating incentives from drug prices and rewarding
innovation according to health-care outcomes’
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In May 2007, health ministers from all member states of the
World Health Organisation will meet at the World Health Assem-
bly in Geneva to discuss the crisis in the current drug development
system. Across the developing world, patients and governments
struggle to access new essential medicines that are too expensive.
At thesame time, healthcare workers intropical countries struggle
to treat common health problems with old, outdated medicines
because too few new ones are being developed [1].
The central question is the impact of intellectual property in
promoting innovation and access to medicines. Most governments
today provide strong intellectual propertyprotection laws for phar-
maceuticals, but this was not always the case. Up until recently,
manygovernmentsconsideredmedicines to betooimportanttobe
subject to market monopolies. As recently as the early 1990s, 48
countries (including Finland, Spain and Portugal) chose to exclude
pharmaceutical products from patentability. Since 1996, however,
the World Trade Agreements have globalized patent protection for
pharmaceuticals by establishing minimum universal standards in
all areas of intellectual property. Governments that previously
provided no or limited patent protection for pharmaceuticals must
now,asWorldTradeOrganization(WTO)members,providepatent
protection for a minimum period of 20 years [2].
Providing intellectual property protection for pharmaceuticals
means implementing a system that minimizes or excludes com-
petition and results in higher drug prices. Although governments
who wantedto be part of theWTOhad toaccept this, itwas argued
that they would beneﬁt in several ways, notably through increased
technology transfer, increased foreign investment in the pharma-
ceutical sector and increased drug development. These beneﬁts are
now being questioned. A ten-year study from Thailand found no
increase in technology transfer and foreign investment as a result
of increased patent protection [3]. As we discuss here, neither has
the rate of innovation improved, particularly in the area of devel-
oping world diseases.
Lack of access, lack of innovation
Lackofaccessandlackofinnovationaretwosidesofthesamecoin.
The patent system is being increasingly criticized on both counts.
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mentation of the WTO Agreements, all new medicines are subject
to patent protection, and this is driving up the price of treatment
in many disease areas; there is little or no competition for newer
medicines and companies offer only limited discounts to a limited
number of countries [4]. Flexibilities exist within the current WTO
rules that allow governments to override pharmaceutical patents
whenever they limit access, but their use is strongly opposed. For
example, in February 2007, the Thai Government, concerned
about the high cost of patented versions of antibiotics, and drugs
for HIV, cancer, cardiovascular and neuropathic problems, issued
compulsory licenses to access generic versions of these medicines.
This move is consistent with WTO and national law, but drug
companies, backed by some Western country governments, were
quick to try and block these efforts [5]. One company, Abbott, has
gone so far as to refuse to register any new medicines in Thailand
until the Thai Government reverses its position on intellectual
property [6].
At the same time, the promise of more innovation that came
with the globalization of patent rules has failed to deliver new
products for neglected diseases. Between 1975 and 2004, of the
1,556 new chemical entities marketed globally, only 20 new drugs
(1.3%) were for tropical diseases and TB, which account for 12% of
the global disease burden [7]. One example of the consequences of
this neglect is TB, which kills up to 2 million people annually. The
current treatment strategy, based on drugs that date from the
1960s, is long and demanding (daily treatment for at least six
months) and compromised by increasing drug resistance [8].
Similarly, treatment for two common tropical diseases, African
sleeping sickness and visceral leishmaniasis (each responsible for
60,000 deaths a year), relies on drugs that are archaic, toxic and
increasingly ineffective owing to drug resistance [9]. There has
been some progress in recent years, notably through the work of
public-private partnerships for neglected-disease drug develop-
ment, but such initiatives are too few and too poorly funded [10].
The poor performance of the patent system in stimulating
innovation is not just a problem for the developing world. A
survey that assessed >3,000 new products approved for the French
market between 1981 and 2004 concluded that 68% of them
brought ‘nothing new’ compared to previously available prepara-
tions [11]. In Canada, a similar study rated barely 5% of all newly
patented drugs as ‘breakthrough’. Drugs classiﬁed as offering no
added therapeutic beneﬁt over existing drugs were responsible for
80% of the rise in prescription costs in Canada [12]. According to
the United Nations Development Programme, <5% of drugs
introduced by the top 25 pharmaceutical companies in the USA
represented true therapeutic advances; of these, 70% were devel-
oped with Government involvement [13].
Another issue is the exploitation of weaknesses in national
patent systems by companies to gain intellectual property protec-
tion for products that do not merit it. Today, many drug patents
are being disputed across the globe. A patent application for
valgancyclovir, a drug used to treat cytomegalovirus infection
in transplant and HIV patients, is currently in dispute in Brazil.
In Thailand, strong opposition by patient groups has led to a
patent application for the combination drug zidovudine–lamivu-
dine to be withdrawn [14], while another AIDS drug patent, for
didanosine, was overturned [15]. In keeping with trade rules, India
amended its Patents Act in 2005 to allow patents for pharmaceu-
tical products to be granted only for real innovations. Novartis is
now challenging the Indian patents act in the Indian court, and
Indian patient groups have launched a campaign to defend the
law. As of March 2007, more than a quarter of a million people
from around the world hadsigned apetition calling for Novartisto
drop its legal action against the Indian Government [16].
Towards a global framework for needs-driven drug R&D
It is this crisis in the patent system that led >280 scientists from 50
countries, including ﬁve Nobel Prize winners, to write to the WHO
in January 2006 to push for the development of an alternative
framework for drug R&D. The authors noted: ‘At a time of huge
progress in basic research science, and more money being spent on
biomedical R&D than ever, we are deeply concerned about the
ability of existing mechanisms to translate this into a global
improvement in public health [...] We see research activities
increasingly complicated by legal restrictions, such as intellectual
property rights, which can interfere with free data exchange and
can limit biomedical research progress. We do not see a good
balance between medical need and resource allocation in the
existing system to support R&D’
*.
Later that year, the WHO Commission on Intellectual Property,
Innovation, and Public Health (CIPIH) released its report [17]. The
report, a result of over three years of research, conﬁrmed the trend
that, whereas patent protection has increased over the past ten
years through the implementation of the WTO agreements, and
further reinforced through bilateral and regional trade agree-
ments, innovation has declined in quantity and quality. More-
over, no evidence was found that the provision of pharmaceutical
patents indeveloping countries isboostinginnovation fordiseases
mainly affecting people in these countries.
The Commission concluded that access and innovation had to
be addressed together, and put forward alternatives to patent
rewards, such as prize funds [18], with the aim of stimulating
R&D without relying on drug sales to fund drug development. The
Commission also recommended that the WHO monitors the
publichealthimpactofintellectualpropertyondrugdevelopment
and access, and suggested developing a plan of action to secure
funding for developing drugs for diseases of the less-developed
world. It also made the point that governments must have a more
proactive role to ensure that health R&D meets real needs, rather
than commercial interests.
These recommendations now need to be translated into actions
throughpoliticalcommitment.Followingonfromtherecommen-
dations of the Commission, the WHO established an Intergovern-
mental Working Group to examine ways to stimulate innovation
while improving access [19]. Within these discussions, several
developing countries arecalling foraglobal R&D framework treaty
thatwouldensurethatallparticipating governments contributeto
R&D for medical innovation in a way that would guarantee
availability and affordability. Further discussions will take place
at the World Health Assembly in May, and throughout 2007.
However, one year since the establishment of the Intergovern-
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*Anon. (2006) Letter submitted 25th January 2006 to members of WHO
Executive Board, Geneva Switzerland.http://homepage.ntlworld.com/
thubbard/whoscientistsletter/English%20Letter.html.
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lmental Working Group, there has been little progress. It is time to
be more concrete.
As these political discussions move forward, pharmaceutical
companies will need to decide where they stand. There are signs
that some companies are willing to explore new ways to be
rewarded for their investments into R&D that do not automati-
cally shut out the world’s poor. At a two-day symposium on TB
drug development in New York in January 2007
y, representatives
from several major pharmaceutical companies, including GSK and
Novartis, endorsed a statement supporting the current discussion
at the WHO for an alternative R&D framework. Such a framework
wouldaddress the questionof whopaysfor essential medicalR&D,
dissociating incentives from drugpricesand rewardinginnovation
according to health care outcomes.
Companiesneedtoengageconstructivelyinthisefforttoexplore
new ways to reward investments into R&D that are not biased
against the world’s poor. With an increasing number of patent
disputesbreakingoutacrosstheglobe,andincreasinggovernmental
concern that the current system is failing to deliver, it is in every-
one’s interest that new mechanisms are found, and soon.
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